Target
$243.89 → $243.92
Current stock research snapshot · 7/31/26 26 days old
RMDResMed
Investment conviction●●○○○2 of 5 · current snapshot
Research target$243.92Current stock price target
Investment thesis statusNEEDS_MORE_DATALast reviewed 7/31/26
Market cap$31.08BSnapshot value · 7/31/26
Research history
See all RMD changes ↗What changed
Healthspan taxonomy seed — see taxonomy_path
ResMed Q2 2026 earnings; CPAP device market share (post-Philips recall); AirView connected health cloud; mask/accessory consumable revenue
Thesis weakens if GLP-1 adoption structurally shrinks OSA treatment volumes, CMS/payer replacement rules loosen compressing the recurring consumables moat, or a competitor wins on network breadth/reimbursement/UX despite device quality. (vault 2026-08)
Neutral — No investor-style discussion found. [X search Aug 2026]
Snapshot · 7/31/26🟡 Mixed · ins-$13.6M · 13F 15+/10-×0.5 · short↓0.26
Snapshot · 7/31/26Timestamped research update
Deep research update
465 words · Updated Aug 9, 2026 · 3 sources
Research in development: this latest 465-word update is published for context while it is expanded toward the 1,000-word editorial standard.
ResMed is a sleep-breathing health platform that sells CPAP machines, masks, replacement parts, and cloud-connected software tools for obstructive sleep apnea and related respiratory care.
FY2026 revenue was $5.653B, up 9.85% YoY versus FY2025, with 61.06% gross margin and 33.37% operating margin on StockAnalysis. ResMed’s Q4 FY2026 release also reported $1.5B in quarterly revenue, up 9% reported / 8% constant currency, and $1.6B in FY2026 free cash flow.
ResMed’s moat is a regulated therapy workflow plus a recurring consumables stack. Its replacement-guidelines page, which says the schedules are based on CMS guidance, shows that patients and providers live inside a cadence of frequent replenishment: full-face cushions every month, nasal cushions/pillows up to twice a month, headgear every 6 months, tubing every 3 months, humidifier water tubs every 6 months, and the CPAP device itself every 5 years. That makes platform switching operationally sticky, not just hardware-expensive.
- FY2026 revenue $5.653B vs. FY2025 $5.146B (+9.85% YoY), gross margin 61.06%, operating margin 33.37%. Source: StockAnalysis financials.
- Q4 FY2026 revenue increased 9% to a record $1.5B; FY2026 gross margin expanded 170 bps to 61.1% and operating margin rose 70 bps to 33.4%. Source: SEC EX-99.1 earnings release dated 2026-08-06.
- Q4 growth was driven by sleep devices, masks, accessories, and software solutions, showing that the franchise is broader than a single SKU. Source: SEC EX-99.1 earnings release.
- ResMed’s replacement-guidelines page states the schedules are based on CMS guidelines and gives component lives ranging from twice a month to every 5 years. Source: ResMed replacement guidelines.
- Management returned $1.0B to shareholders in FY2026 and guided to more than $1.85B in FY2027 capital returns, suggesting strong cash conversion and no balance-sheet stress. Source: SEC EX-99.1.
The moat is the regulated adherence workflow, not just the device. Each switch forces a re-fit, a new supply schedule, and a re-run of the prescription/payer/provider stack. The recurring consumables cadence turns the installed base into a replenishment engine and makes channel displacement hard.
- GLP-1 adoption could shrink some obstructive sleep apnea treatment volumes over time.
- If CMS or payer replacement rules loosen, the recurring consumables moat could compress.
- A competitor that wins on network breadth, reimbursement handling, or software UX could erode share even if device quality remains high.
- What is the exact mix of device, masks/accessories, and software revenue?
- How much of recent growth is share gain versus underlying sleep-apnea prevalence?
- Would a change in CMS replacement guidance materially alter the replenishment economics?
STRENGTHENED
ResMed looks like a classic healthspan toll road: regulated therapy, recurring consumables, and cloud-connected care. The new earnings release confirms continued growth and margin expansion, while the replacement-guidelines page makes the switching friction concrete.
Primary and supporting material
Sources
3 sources preserved from the latest qualified research update.